Form 8-K · Current Report · Filed 2025-05-08
Cidara Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Cidara Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2025, and provided updates on its clinical trials and business operations. The company's cash, cash equivalents, and restricted cash totaled $174.5 million as of March 31, 2025, down from $196.2 million at the end of 2024. Collaboration revenue was zero for Q1 2025 compared to $1.0 million in Q1 2024, as the Janssen Collaboration Agreement was terminated in April 2024. R&D expenses increased to $24.6 million from $5.9 million in the prior year, driven by the ongoing Phase 2b NAVIGATE study and higher personnel costs. General and administrative expenses rose to $6.2 million from $3.6 million. The company reported a net loss of $23.5 million for Q1 2025. Cidara also provided updates on its clinical trials, including the data cutoff date for the Phase 2b NAVIGATE trial and expectations for top-line data in late June 2025.
- Filer
- Cidara Therapeutics Inc. CDTX · NASDAQ
- Filed
- Accession
- 0001610618-25-000045
- CIK
- 0001610618
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$18.98
Next session
-1.8%
Since filing
+1066.4%
Latest close
$221.38
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from CDTX reporting the same item, with the next session's move:
Exhibits (1)
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Never miss another CDTX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.